Pascal Soriot spoke exclusively with CNBC from the site of AstraZeneca's new $1 billion R&D facility in Kendall Square in ...

Oct 5 (Reuters) - AstraZeneca said on Monday it would spend more than $1 billion in Massachusetts as part of its broader $50 ...

Pascal Soriot told CNBC that ivonescimab could combine with antibody-drug conjugates to treat tumors that existing ...

The biopharmaceutical company plans to expand its Massachusetts workforce by over 50% as the industry faces broader headwinds ...

The investment is expected to increase the pharma giant's workforce in Massachusetts to 3,000 employees within a few years.

CNBC’s Annika Kim Constantino and Pascal Soriot, AstraZeneca CEO, join 'The Exchange' to discuss its $50 billion investment in stateside manufacturing and opening an research and development site in ...

AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical ...

AstraZeneca today announced the opening of its newest global strategic research and development (R&D) center, in Kendall Square, Cambridge, Massachusetts. The new state-of-the-art facility builds on ...

Summit shares surged in after-hours trading following the news of AstraZeneca’s investment, as the two companies plan to ramp ...

CNBC’s Annika Kim Constantino and Pascal Soriot, AstraZeneca CEO, join 'The Exchange' to discuss its $50 billion investment ...

AstraZeneca is investing $2 billion in Summit Therapeutics to accelerate the development of PD-1xVEGF bispecific ivonescimab ...